Aspect Biosystems And Jsr Corporation Enter Collaboration To Develop Bioprinted Vascularized Tissues For Regenerative Medicine
The launch of this new collaboration builds on Aspect`s existing partnership with JSR Corporation
VANCOUVER, British Columbia -- Aspect Biosystems, a privately held biotechnology company pioneering the development of bioprinted therapeutics, is pleased to announce a new joint development program with JSR Corporation, a global leader in advanced materials innovation. This collaboration builds on the existing partnership between the two companies and will see the combining of Aspect’s proprietary microfluidic 3D bioprinting platform with JSR’s advanced materials technology to develop implantable vascularized tissues for kidney regeneration and other applications in regenerative medicine.
The vascularized implantable tissues we develop through this collaboration will enable the next generation of regenerative medicine solutions by supporting longer-term function of therapeutic cells in the body,” said Tamer Mohamed, President and CEO of Aspect Biosystems. “We are excited to work with JSR’s innovative team based in Japan, a country at the forefront of regenerative medicine, and we look forward to continue making breakthroughs with our broadly applicable technology platform.”
“In our work through JSR Life Sciences, we are seeing the need for advanced, innovative materials continue to grow throughout the biosciences,” said Toru Kimura, CTO of JSR Corporation. “This joint development program with Aspect Biosystems is testament to that and an important step in enabling and accelerating highly impactful areas in regenerative medicine.”